Climb Bio (CLYM) Current Assets (2020 - 2026)
Climb Bio's (CLYM) quarterly Current Assets came in at $113.4 million in Q1 2026, up 13.09% YoY from $100.3 million in Q1 2025, and up 7.14% on a QoQ basis from $105.8 million in Q4 2025.
Climb Bio (CLYM) Current Assets (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Current Assets data on file, last reported at $113.4 million in Q1 2026.
- Quarterly Current Assets rose 13.09% year-over-year to $113.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.4 million (up 13.09% YoY) and the FY2025 annual result came in at $105.8 million, down 31.65% from the prior year.
- Current Assets climbed to $113.4 million in Q1 2026, from $105.8 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $226.0 million in Q2 2024 to a low of $87.4 million in Q2 2025.
- A 5-year average of $128.0 million and a median of $114.2 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets soared 97.82% — and 2025, when it sank 61.33%.
- Tracing CLYM's Current Assets over 5 years: stood at $134.4 million in 2022, then declined by 17.96% to $110.3 million in 2023, then soared by 40.47% to $154.9 million in 2024, then tumbled by 31.65% to $105.8 million in 2025, then gained by 7.14% to $113.4 million in 2026.
- The last three Current Assets figures came in at $113.4 million (Q1 2026), $105.8 million (Q4 2025), and $91.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 186.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 186.64 Mn |
| Mar 31, 2026 | 113.40 Mn |
| Dec 31, 2025 | 105.85 Mn |
| Sep 30, 2025 | 90.96 Mn |
| Jun 30, 2025 | 87.38 Mn |
| Mar 31, 2025 | 100.28 Mn |
| Dec 31, 2024 | 154.87 Mn |
| Sep 30, 2024 | 197.61 Mn |
| Jun 30, 2024 | 226.00 Mn |
| Mar 31, 2024 | 109.22 Mn |
| Dec 31, 2023 | 110.26 Mn |
| Sep 30, 2023 | 112.43 Mn |
| Jun 30, 2023 | 114.24 Mn |
| Mar 31, 2023 | 120.17 Mn |
| Dec 31, 2022 | 134.39 Mn |
| Sep 30, 2022 | 133.17 Mn |
| Jun 30, 2022 | 133.08 Mn |
| Mar 31, 2022 | 133.28 Mn |
| Dec 31, 2021 | 148.25 Mn |
| Sep 30, 2021 | 158.63 Mn |